GCA
LGND icon

Gideon Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Gideon Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,992
Closed -$424K – 353
2017
Q3 		$424K Buy
+4,992
New +$395K 0.42% 68
2017
Q1 		– Sell
-6,071
Closed -$385K – 457
2016
Q4 		$385K Buy
+6,071
New +$383K 0.25% 155

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gideon Capital Advisors's LGND Position: Q4 2017 in Review

Gideon Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 4,992 shares — an estimated $424K sold.

Gideon Capital Advisors first reported a position in LGND in Q4 2016 and held it in 2 quarters. The position peaked at $424K in Q3 2017. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

  • Gideon Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Gideon Capital Advisors sold 4,992 Ligand Pharmaceuticals shares in Q4 2017, an estimated $424K.
  • Gideon Capital Advisors first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Gideon Capital Advisors's Ligand Pharmaceuticals position peaked at $424K in Q3 2017.
  • 298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Gideon Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.